hi Ceviche
Msta access report
think it's OPT Opthea
they mention it in their report as being at a comparable testing stage.
Still doesn't explain their assumption for revenue in 2021? Maybe it's to do with when a licensing deal with a potential big pharma would be expected to start so whilst they would get all the gross revenue 2020 in 2021 they would get say 15% or something like that on Aussie sales only through the Provisional Scheme then revenue quickly ramps up after end of trials in 2022 for US EU sales????
be nice if they added some assumptions to the report
hi CevicheMsta access reportthink it's OPT Optheathey...
-
- There are more pages in this discussion • 64 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
26.0¢ |
Change
0.005(1.96%) |
Mkt cap ! $90.94M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 27.0¢ | 25.5¢ | $154.4K | 596.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 68618 | 25.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 5263 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |